Suppr超能文献

猪体内五种非去极化肌松药的肺首过摄取情况。

The pulmonary first-pass uptake of five nondepolarizing muscle relaxants in the pig.

作者信息

Beaufort T M, Proost J H, Houwertjes M C, Roggeveld J, Wierda J M

机构信息

Research Group for Experimental Anesthesiology and Clinical Pharmacology, University of Groningen, The Netherlands.

出版信息

Anesthesiology. 1999 Feb;90(2):477-83. doi: 10.1097/00000542-199902000-00023.

Abstract

BACKGROUND

It is not known whether the lungs influence the early pharmacokinetics of muscle relaxants and, if they do, whether differences in pulmonary uptake contribute to the differences in potency and/or onset time among muscle relaxants. Because the lungs are uniquely positioned, receive the entire cardiac output, have a large capillary surface area, and can temporarily store various basic drugs, the authors determined whether substantial pulmonary first-pass uptake of muscle relaxants occurs.

METHODS

In 14 pigs, rocuronium, vecuronium, Org 9487, Org 7617, or d-tubocurarine were administered simultaneously with indocyanin green within 1 s into the right ventricle, and then arterial blood was sampled every 1.2 s (in the first min). The tibialis muscle response was registered mechanomyographically.

RESULTS

The maximum block was 93% (68-100% [median and range]). Onset times ranged from 83 s (78-86 s) for rocuronium to 182 s (172-192 s) for d-tubocurarine. Fraction-versus-time outflow curves showed that the peak of muscle relaxants and indocyanin green occurred almost simultaneously. Pulmonary first-pass retention was negligible. The retention of muscle relaxants at 95% passage of indocyanin green was -9% (-31 to 18%). The difference in the mean transit time between muscle relaxant and indocyanin green was 1.0 (0.8 to 1.4), 0.2 (-0.8 to 0.3), 0.3 (0.2 to 0.4), 0.5 (0.2 to 1.3), and -2.2 s for rocuronium, vecuronium, Org 9487, Org 7617, and d-tubocurarine, respectively.

CONCLUSIONS

There is no substantial pulmonary first-pass uptake of rocuronium, vecuronium, Org 9487, Org 7617, or d-tubocurarine in pigs. Therefore, differences in pulmonary first-pass uptake do not contribute to the differences in potency and/or onset time among muscle relaxants.

摘要

背景

尚不清楚肺是否会影响肌松药的早期药代动力学,若有影响,肺摄取差异是否会导致不同肌松药在效价和/或起效时间上存在差异。由于肺所处位置独特,接受全部心输出量,具有大的毛细血管表面积,且能暂时储存多种碱性药物,因此作者研究了肌松药是否存在显著的肺首过摄取。

方法

对14头猪在1秒内将罗库溴铵、维库溴铵、Org 9487、Org 7617或d -筒箭毒碱与吲哚菁绿同时注入右心室,然后在第1分钟内每隔1.2秒采集动脉血样。通过肌动图记录胫前肌反应。

结果

最大阻滞率为93%(68 - 100%[中位数和范围])。起效时间从罗库溴铵的83秒(78 - 86秒)到d -筒箭毒碱的182秒(172 - 192秒)不等。分数-时间流出曲线显示肌松药和吲哚菁绿的峰值几乎同时出现。肺首过保留可忽略不计。在吲哚菁绿95%通过时,肌松药的保留率为 - 9%(- 31%至18%)。罗库溴铵、维库溴铵、Org 9487、Org 7617和d -筒箭毒碱的肌松药与吲哚菁绿平均通过时间差异分别为1.0(0.8至1.4)、0.2(- 0.8至0.3)、0.3(0.2至0.4)、0.5(0.2至1.3)和 - 2.2秒。

结论

猪体内罗库溴铵、维库溴铵、Org 9487、Org 7617或d -筒箭毒碱不存在显著的肺首过摄取。因此,肺首过摄取差异不会导致不同肌松药在效价和/或起效时间上存在差异。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验